These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 20072655)
21. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
22. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. Gong A; Ge N; Yao W; Lu L; Liang H Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724 [TBL] [Abstract][Full Text] [Related]
24. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800 [TBL] [Abstract][Full Text] [Related]
25. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108 [TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
27. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. Ducray F; del Rio MS; Carpentier C; Psimaras D; Idbaih A; Dehais C; Kaloshi G; Mokhtari K; Taillibert S; Laigle-Donadey F; Omuro A; Sanson M; Delattre JY; Hoang-Xuan K J Neurooncol; 2011 Feb; 101(3):457-62. PubMed ID: 20556480 [TBL] [Abstract][Full Text] [Related]
28. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
29. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. Lan F; Pan Q; Yu H; Yue X J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372 [TBL] [Abstract][Full Text] [Related]
30. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289 [TBL] [Abstract][Full Text] [Related]
32. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431 [TBL] [Abstract][Full Text] [Related]
33. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105 [TBL] [Abstract][Full Text] [Related]
34. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862 [TBL] [Abstract][Full Text] [Related]
35. KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation. Yu G; Wu F; Wang E Cell Physiol Biochem; 2016; 38(4):1596-604. PubMed ID: 27081861 [TBL] [Abstract][Full Text] [Related]
36. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related]
37. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
38. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141 [TBL] [Abstract][Full Text] [Related]
39. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760 [TBL] [Abstract][Full Text] [Related]
40. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]